BACKGROUND AND OBJECTIVE: The cardiac safety of digoxin therapy for congestive heart failure (CHF) is a source of concern, especially among those with renal impairment. METHODS: Using a case-control design, we examined the risk of primary cardiac arrest (PCA) associated with digoxin therapy within three levels of renal function. RESULTS: After adjustment for other clinical characteristics, digoxin therapy for CHF was not associated with an increased risk of PCA [odds ratio (OR)=0.97, 95% confidence interval (CI) 0.59-1.62] among patients with normal renal function (serum creatinine </=1.1 mg/dL). In contrast, digoxin therapy was associated with a modest increase in risk (OR=1.58, CI 0.89-2.80) among patients with mild renal impairment (serum creatinine=1.2-1.4 mg/dL); and a twofold increase in risk (OR=2.39, CI 1.37-4.18) among patients with moderate renal impairment (serum creatinine=1.5-3.5 mg/dL). CONCLUSIONS: These findings suggest that the risks of digoxin may offset the benefits among patients with moderately impaired renal function, but not among patients with normal renal function.
BACKGROUND AND OBJECTIVE: The cardiac safety of digoxin therapy for congestive heart failure (CHF) is a source of concern, especially among those with renal impairment. METHODS: Using a case-control design, we examined the risk of primary cardiac arrest (PCA) associated with digoxin therapy within three levels of renal function. RESULTS: After adjustment for other clinical characteristics, digoxin therapy for CHF was not associated with an increased risk of PCA [odds ratio (OR)=0.97, 95% confidence interval (CI) 0.59-1.62] among patients with normal renal function (serum creatinine </=1.1 mg/dL). In contrast, digoxin therapy was associated with a modest increase in risk (OR=1.58, CI 0.89-2.80) among patients with mild renal impairment (serum creatinine=1.2-1.4 mg/dL); and a twofold increase in risk (OR=2.39, CI 1.37-4.18) among patients with moderate renal impairment (serum creatinine=1.5-3.5 mg/dL). CONCLUSIONS: These findings suggest that the risks of digoxin may offset the benefits among patients with moderately impaired renal function, but not among patients with normal renal function.
Authors: Bennett W Baugher; Marvin Berman; Jennifer E Dierksen; David A Armbruster; Amitava Dasgupta Journal: J Clin Lab Anal Date: 2014-03-22 Impact factor: 2.352
Authors: Sara Modig; Christina Lannering; Carl Johan Ostgren; Sigvard Mölstad; Patrik Midlöv Journal: BMC Geriatr Date: 2011-01-11 Impact factor: 3.921